Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Pharm Gp LSE:OXP London Ordinary Share GB00B3LXPB43 ORD 0.001P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 1.50p 0 05:00:01
Bid Price Offer Price High Price Low Price Open Price
1.45p 1.55p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.80 -1.90 -0.11 18.1

Oxford Pharm Gp (OXP) Latest News

Real-Time news about Oxford Pharm Gp (London Stock Exchange): 0 recent articles
More Oxford Pharm Gp News
Oxford Pharm Gp Takeover Rumours

Oxford Pharm Gp (OXP) Share Charts

1 Year Oxford Pharm Gp Chart

1 Year Oxford Pharm Gp Chart

1 Month Oxford Pharm Gp Chart

1 Month Oxford Pharm Gp Chart

Intraday Oxford Pharm Gp Chart

Intraday Oxford Pharm Gp Chart

Oxford Pharm Gp (OXP) Discussions and Chat

Oxford Pharm Gp Forums and Chat

Date Time Title Posts

Add a New Thread

Oxford Pharm Gp (OXP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Oxford Pharm Gp trades in real-time

Oxford Pharm Gp (OXP) Top Chat Posts

cpap man: Yes barnetpeter but with a bowl comes a cup & handle formation! So a pull back in the OXP share price in the very short term but all of this of course bodes really well for the medium to long term!
timbo003: >>>>lucky Mouse I have absolutely no idea where the share price is going in the short term, I just know that the technology (if you can call it that) is fundamentally flawed. I have been saying this for the last 3-4 years, all the way from around 3p, up to 12p and back down again to sub 2p
master rsi: Going places now on a very narrow spread 2.45 v 2.50p +0.20p level 2 is 1 v 1 the last 2 days of large volume is working wonders fro the share price now
master rsi: Bought some, as the volume and bouncing from bottom looks interesting my take was....... Large volume 40.4M at LSE and 3.3M at ISDX, share price bounce today after a fall from 7.75p this year and 13.50p last year. Cash rich £22M worth 1.82p, so 80% is in cash and the rest of the company has almost no value.
timbo003: The law of gravity prevails. At 4,5p/share the market cap is still around £55m, which is still way too high for a biotech company which has IP worth zilch and a development portfolio stuffed full of white elephants. Cash in the bank must be around £20m, which corresponds to a share price of around 1.6p/share, which is probably all they are worth.
timbo003: >>> supernumerary I don't know whether you spotted it, but Pozen shares have done quite well since the last mention on June 4th (up around 40%) Presumably it’s mainly down to corporate action and proposed new domicile which was announced on June 8th: It sounds very much like the problem with the FDA approval on Yosprala is with the Aspirin supplier. Failing two audits on the trot is unforgivable and I suspect Pozen will now go with another supplier. I’m not sure why they didn’t register an alternative Aspirin supplier in their NDA when they first submitted, the pharma companies I used to work for always used to register at least 2 suppliers for all their applications (and they probably still do). I'm surprised Sanofi signed up with Pozen for Yosprala in the first place. Big pharma tend to go after much bigger deals ($1Bn plus). I cannot see that Yosprala sales are going to be anything like that, given the widespread availability of other “safer” enteric coated aspirin and buffered aspirin which sell for a few cents a tablet: If Pozen do go with a partner for Yosprala, I suspect they will end up with a smaller niche player and perhaps have different partners in different jurisdictions, or maybe (post merger) they will decide to go it alone. >>>>Cheshire man If you like the idea of having Woodford on board on your healthcare investments, there are other (better) alternatives around and I suggest you take a look at these two: Synairgen (SNG): Market cap just £34M, Woodford bought higher up than the current price, they already have a partner for their lead drug (Astra Zeneca), the AGM is on Monday when I suspect we will get an update on the pipeline Sphere Medical (SPHR): Market cap just £22M, share price is at an all time low, Woodford bought in during the recent placing at the current share price (Chris Evans bought a large stake too), Ortho Clinical diagnostics own a sizable stake too. Their main product (Proxima 3) has just launched (no sales feedback yet). The shares are currently being held back by a large overhang (which cannot last forever). Compare and contrast these two with OXP which has a market cap of £120M, no partner and the only clinical data they have is on on two different products, neither of which were bioequivalent to the reference products, which is a potential show stopper for both of them.
timbo003: Yes burbelly I guess it has 10 bagged from the lows, well done. I'm not really concerned with the share price and I think I have acknowledged on a number of occasion that the share price is likely to rise on speculative buying. I'm more interested in the technology than share price gyrations. Having worked in the area for quite a few years it is mainly of academic interest to me.
timbo003: doodlebug, I have been following this share for 2 years (almost to the day). First of all I do not recall making any predictions on the short term share price as that is mainly down to sentiment, not fundamentals. It would not surprise me if the share price rose further in the next few weeks in anticipation of the next clinical results, even though in my view it definitely wouldn't be justified. Since the beginning of 2013 I have consistently pointed out that the Statin and NSAID programs are extremely risky. In the last 2 years OXP have conducted just one clinical study and as you know that failed to meet all of its end points (i.e. it was a failure). This has resulted in a delay of one around year in the timeline for the ibuprofen program. The company has gone very quiet on the Statin development (they were supposed to conduct a proof of concept clinical initially in 2013 and then it was 2014), is this delay because they have been advised that the scientific rationale for safe-stat is flawed? My views have been vindicated up to now, therefore I will just carry on with the commentary.
doodlebug4: I don't know if dreamcatcher reads this thread, he flagged up OXP many years ago on Money-m and I bought in when the share price was 4p in February 2013. Well done dc.It just goes to show if you believe in a company and have patience with the share price then stick with it. Timbo, you have been posting negative comments on this thread about the product and the company for years, why not give it a rest.
timbo003: Doodlebug, I don't recall that I ever made any predictions on the short term price movements on OXP and I cannot recall making any "tips" recently, perhaps you are confusing me with someone else. I have however given my views on the probability of a successful outcome of the forthcoming study on OXP001 and that hasn't changed. I strongly believe the study will fail to show a clinically meaningful difference between OXP001 and control. I suspect (but cannot be sure) that the share price will react extremely negatively to this news when it appears, which will probably be in Q3 this year. You may not like this view, you may disagree with this view, but just because the OXP share price has risen recently, does not make my views on the prospects of the OXP001 any less valid. Why don't you try and come up with some valid reasons for why I am wrong about OXP001, instead of writing derogatory one liners, which add nothing to our collective knowledge? I chose to comment on this particular share and some other pharma shares that I also do not own, as I believe that collectively we will be all be better informed and better off if we share information. I also think it is useful to keep an accountable record of ongoing thoughts on investments and potential investments, as it can only help in refining our individual investment approach. I have a deeper insight into the pharma industry and the pharmaceutical development process than most other investors here, which is why I comment on shares in this sector. For OXP I have given an unbiased, critical appraisal on the prospects for OXP001, OXP003 and OXP004. I have been complementary on OXP's current taste masking business, non-judgemental on the prospects of OXP002 and I have commented positively on the recent share purchases by the chairman and the CEOs share option package. I have no money at stake here. If I am incorrect, I only stand to lose my pride and perhaps my appetite for Burbelly's pies! You can ignore what I write if you wish, but you will be less informed as a result. Hit Counter Hits since October 24th 2013
Oxford Pharm Gp share price data is direct from the London Stock Exchange
Your Recent History
Oxford Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181213 11:29:11